YOLFTbeta
OKYO Pharma Limited

OKYO Pharma Limited

OKYO · NASDAQ · Healthcare / Biotechnology

1.35USD-0.05 (-3.57%)

Price History

Full chart

Market Stats

Previous Close1.40
Open1.41
Day Range1.20 – 1.41
52-Week Range1.28 – 3.20
Volume264.10K
Market Cap72.42M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.24
Dividend Yield0.00%
Beta0.00
50-Day Avg1.50
200-Day Avg1.71

About

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Robert J. Dempsey M.B.A.
  • Employees5
  • Headquarters35a Albemarle St, London, United Kingdom, W1S 4JE, USA
  • Websitehttps://okyopharma.com

Leadership

  • Mr. Robert J. Dempsey M.B.A.CEO & Executive Director
  • Ms. Keeren ShahChief Financial Officer · b. 1976
  • Dr. Rajkumar Patil Ph.D.Chief Scientific Officer · b. 1959
  • Dr. Gary S. Jacob Ph.D.Chief Development Officer & Director · b. 1947
  • Dr. Flavio Mantelli M.D., Ph.D.Chief Medical Officer
  • Mr. Michael Paul BeckFounder · b. 1957

Financials

Income Statement

Currency: USD2008-03-312009-03-312010-03-312011-03-312012-03-312013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Revenue-----------00000000
Cost of Revenue----77.24K------219.175.97K811.50K13.00K6.75M7.51M2.56K6.69M
Gross Profit------------219-5.97K-811.50K-13.00K-6.75M-7.51M-2.56K-6.69M
Operating Expense-----------4.54M1.51M3.32M6.22M6.34M8.24M7.19M1.81M
Operating Income-3.17M15.10M28.61M-1.70M-5.11M-4.92M-4.77M-1.75M-1.12M-363.27K-28.29M-4.54M-1.52M-4.13M-6.23M-13.09M-15.75M-7.19M-8.50M
EBITDA-2.90M15.10M33.93M-1.70M-5.09M-4.70M-4.67M2.52M-1.14M-363.27K26.17M-4.54M-1.51M-4.12M-6.21M-13.08M-15.75M-7.08M-8.47M
Net Income-2.97M14.33M12.67M-1.62M-4.80M-4.84M-13.95M-8.26M-820.17K-241.93K-28.30M-4.89M-1.54M-3.35M-5.43M-13.27M-16.83M-4.71M-8.95M
R&D-----------3.04M517.46K348.35K1.61M6.34M8.24M2.25M1.81M
Interest Expense174.00K266.00K1.00K88.00K13.00K61.35K4.14K11.68K8.60K3.54K001.16K1.12K096.69K1.05M883.65K473.94K

Balance Sheet

Currency: USD2008-03-312009-03-312010-03-312011-03-312012-03-312013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Assets27.60M38.27M54.13M16.09M42.20M45.20M47.21M34.05M32.18M27.76M2.01M759.86K597.40K7.09M4.30M5.20M1.54M3.68M20.98M
Total Liabilities144.86K85.96K79.87K78.74K832.89K183.32K247.95K151.07K181.34K258.76K91.06K426.72K737.20K1.77M1.35M7.26M7.42M9.23M8.64M
Total Equity27.46M38.18M54.05M16.01M41.34M45.02M46.96M33.90M32.00M27.50M1.92M333.14K-139.80K5.32M2.95M-2.05M-5.88M-5.55M12.34M
Cash17.97M5.38M26.64M16.07M17.03M14.34M11.82M6.47M5.13M3.93M2.01M627.56K234.96K6.89M2.70M4.05M826.85K1.56M14.59M
Total Debt------------25.56K98.76K-2.22M---
Net Debt-17.97M-5.38M-26.64M-16.07M-17.03M-14.34M-11.82M-6.47M-5.13M-3.93M-2.01M-627.56K-209.40K-6.79M-2.70M-1.83M-826.85K-1.56M-14.59M

Cash Flow

Currency: USD2008-03-312009-03-312010-03-312011-03-312012-03-312013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Operating Cash Flow-513.95K-226.35K-878.61K-1.31M-4.67M-3.82M-3.45M-1.42M-650.88K-651.27K-1.59M-1.99M-1.20M-1.60M-5.47M-7.70M-9.49M-1.81M-5.94M
Investing Cash Flow-2.82M-11.27M20.82M29.14M-4.12M-7.18M-10.59M-2.76M-335.18K-375.39K-1.01K-1.32K-132.67K-18.11K-1.67K-5.92K--1.21K-6.01M
Financing Cash Flow21.30M3.91M1.03M-40.17M9.25M8.69M10.43M370.51K12.36K4.42K774.30K774.30K963.31K7.83M2.15M9.32M6.21M2.66M25.02M
Capital Expenditure2.82M717.73K003.51M7.18M10.65M2.76M406.05K375.39K1.01K1.32K5.03K6.94K1.67K5.92K31.21K6.08K
Free Cash Flow-3.33M-944.09K-878.61K-1.31M-8.18M-11.00M-14.10M-4.18M-1.06M-1.03M-1.59M-1.99M-1.20M-1.61M-5.47M-7.70M-9.49M-1.81M-5.94M
Dividends Paid---40.74M---------------
FCF to OCF648.65%417.09%100.00%100.00%175.15%287.91%408.36%294.68%162.38%157.64%100.00%100.07%100.00%100.43%100.03%100.08%100.00%100.07%100.10%
Dividend Paid to FCF----3110.67%---------------

Earnings

Report DateAug 15, 2023Dec 28, 2023Jan 9, 2024Mar 31, 2024Jul 30, 2024Sep 30, 2024Jan 29, 2025Mar 31, 2025Aug 5, 2025Sep 30, 2025Feb 25, 2026Mar 31, 2026
EPS Estimate-0.11-0.11-0.10-0.09-0.09-0.09-0.09-0.05-0.05-0.02-0.04-0.03
EPS Actual-0.34-0.11-0.10--0.09--0.08--0.06-0.00-
Surprise-209.09%0.00%0.00%-0.00%-11.11%--20.00%-100.00%-
TimingPre-marketPre-marketAfter-hours---------

Key Statistics & Ratios

Market Cap72.42M
Enterprise Value64.19M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book5.53
EPS-0.24
Book Value0.235
Revenue (TTM)0
Gross Profit (TTM)-6.69M
EBITDA-8.50M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-263.78%
Return on Assets-43.10%
Shares Outstanding52.48M
Shares Float27.93M
Beta0.00
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 1 analystsTarget 8.33
  • Buy
    1

Ownership Breakdown

Institutions
20.12%
Insiders
31.13%
Retail / Other
48.75%

Top Institutional Holders

  • Woodline Partners LP
    3.65M6.96%
  • MAVEN SECURITIES Ltd
    1.18M2.24%
  • Stonepine Capital Management Llc
    850.00K1.62%
  • Balyasny Asset Management LLC
    584.80K1.11%
  • Opaleye Management Inc
    375.20K0.71%
  • UBS Group AG
    59.76K0.11%
  • XTX Topco Ltd
    37.65K0.07%
  • RSM US WEALTH MANAGEMENT LLC
    33.26K0.06%
  • HPM Partners LLC
    12.81K0.02%
  • Geode Capital Management, LLC
    12.09K0.02%
  • Dauntless Investment Group, LLC
    3.82K0.01%
  • EFG International AG
    9230.00%
  • Advisor Group Holdings, Inc.
    1520.00%
  • Continuum Advisory, LLC
    500.00%
  • Morgan Stanley - Brokerage Accounts
    100.00%
  • Wealth Enhancement Advisory Services, LLC
    00.00%
  • Renaissance Technologies Corp
    00.00%

Top Fund Holders

  • Fidelity Nasdaq Composite Index
    12.09K0.02%